Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.38 |
| ▸ | CTSB | P07858 | 8/20 | 0.38 |
| ▸ | CTSS | P25774 | 7/20 | 0.38 |
| ▸ | CTSK | P43235 | 7/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52055 | 0.71 | CTSS (0.46) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL1117743 | 0.70 | CTSL (0.39) | CTSLCTSBCTSSCTSKSIGMAR1 | |
| SCHEMBL5672448 | 0.66 | CCR6 (0.49) | SIGMAR1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL854095 | 0.66 | CTSL (0.53) | CTSLCTSBCTSSCTSKSIGMAR1 | |
| SCHEMBL9900857 | 0.65 | CTSL (0.39) | CTSLCTSBCTSSCTSKSIGMAR1 | |
| SCHEMBL11110649 | 0.64 | ALDH1A1 (0.50) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL8727723 | 0.63 | ALOX5 (0.53) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL18765832 | 0.63 | ALDH1A1 (0.49) | SIGMAR1RORCALDH1A1MAPTKMT2A | |
| SCHEMBL633907 | 0.63 | SIGMAR1 (0.54) | SIGMAR1CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL633302 | 0.63 | SIGMAR1 (0.54) | SIGMAR1CHRM2CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CTSL 3453/4885CTSB 2999/4885CTSS 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.